ReviewGut and liver2014
Barrett's esophagus and cancer risk: how research advances can impact clinical practice.
Review in Gut and liver, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02464930 (Evaluation of MicroRNA Expression in Blood and Cytology Specimens as a Novel Method for Detecting Barrett's Esophagus), which is not on this map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Evaluation of MicroRNA Expression in Blood and Cytology Specimens as a Novel Method for Detecting Barrett's Esophagus
Who cites it
20 citing papers in PubMed.
- E-cigarette use and Barrett's esophagus: evaluating a new risk in the era of vaping.Esophagus : official journal of the Japan Esophageal Society · 2026Article
- Epigenetic biomarkers and the progression of Barrett's oesophagus to oesophageal adenocarcinoma: a systematic review protocol.Systematic reviews · 2026Article
- Surveillance of Barrett's Esophagus Patients in an Expert Center is Associated With Low Disease-Specific Mortality.United European gastroenterology journal · 2025Article
- Neutrophil-Lymphocyte Ratio May be Used as a Biomarker for Predicting Progression of Barrett's Esophagus to Esophageal Adenocarcinoma: A Retrospective Cohort Study.JGH open : an open access journal of gastroenterology and hepatology · 2025Article
- Advancements in Barrett's esophagus detection: The role of artificial intelligence and its implications.World journal of gastroenterology · 2024Article
- Systemic Diseases and Gastrointestinal Cancer Risk.Journal of cancer & allied specialties · 2023Review
- The Use of miRNAs in Predicting Response to Neoadjuvant Therapy in Oesophageal Cancer.Cancers · 2022Review
- Evolutionary dynamics in Barrett oesophagus: implications for surveillance, risk stratification and therapy.Nature reviews. Gastroenterology & hepatology · 2022Review
- Novel In Vivo Mouse Cryoablation Model to Explore Unique Therapeutic Approaches for Premalignant Columnar Lesions.Methods and protocols · 2021Article
- Detection of circulating BMP5 as a risk factor for Barrett's esophagus.Scientific reports · 2020Article
- Establishing spectrochemical changes in the natural history of oesophageal adenocarcinoma from tissue Raman mapping analysis.Analytical and bioanalytical chemistry · 2020Article
- Associations between the severity of reflux esophagitis in children and changes in oxidative stress, serum inflammation, vasoactive intestinal peptide and motilin.Experimental and therapeutic medicine · 2019Article
- High-Fat Diet Accelerates Carcinogenesis in a Mouse Model of Barrett's Esophagus via Interleukin 8 and Alterations to the Gut Microbiome.Gastroenterology · 2019Article
- Implications for Tumor Microenvironment and Epithelial Crosstalk in the Management of Gastrointestinal Cancers.Journal of oncology · 2019Review
- Screening and Surveillance for Barrett's Esophagus: Is It Cost-Effective?Digestive diseases and sciences · 2018Review
- Oesophageal cancer.Nature reviews. Disease primers · 2017Review
- Oesophageal Stem Cells and Cancer.Advances in experimental medicine and biology · 2017Article
- Adenocarcinoma of Cervical Esophagus Arising in the Barrett's Mucosa.Indian journal of surgical oncology · 2015Article
- Surveillance in Barrett esophagus.Journal of medicine and life · 2014Article
- Barrett's esophagus: lessons from recent clinical trials.Annals of gastroenterologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Barrett's esophagus (BE) is the only known precursor to esophageal adenocarcinoma (EAC), whose incidence has increased sharply in the last 4 decades. The annual conversion rate of BE to cancer is significant, but small. The identification of patients at a higher risk of cancer therefore poses a clinical conundrum. Currently, endoscopic surveillance is recommended in BE patients, with the aim of diagnosing either dysplasia or cancer at early stages, both of which are curable with minimally invasive endoscopic techniques. There is a large variation in clinical practice for endoscopic surveillance, and dysplasia as a marker of increased risk is affected by sampling error and high interobserver variability. Screening programs have not yet been formally accepted, mainly due to the economic burden that would be generated by upper gastrointestinal endoscopy. Screening programs have not yet been formally accepted, mainly due to the economic burden that would be generated by widespread indication to upper gastrointestinal endoscopy. In fact, it is currently difficult to formulate an accurate algorithm to confidently target the population at risk, based on the known clinical risk factors for BE and EAC. This review will focus on the clinical and molecular factors that are involved in the development of BE and its conversion to cancer and on how increased knowledge in these areas can improve the clinical management of the disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.